We have evaluated the effects of L-DOPA and carbidopa treatment (30 days) on dopamine (DA) turnover, intracellular cyclic AMP (cAMP) accumulation and tetrahydrobiopterin levels in the nigrostriatal pathway of rats with a unilateral 6-OHDA lesions (greater than 90% lesions). We observed significant increase in the 3,4-dihydroxy-phenylacetic acid/DA and homovanillic acid/DA ratios, and in basal cAMP levels (92%) in the ipsilateral striatum, but not in the substantia nigra when compared to the contralateral intact hemisphere. After L-dopa/carbidopa treatment, the increased 3,4-dihydroxy-phenylacetic acid/DA, homovanillic acid/DA ratios and the elevated levels of cAMP in the ipsilateral striatum were reduced significantly and returned to the control levels of contralateral non-lesioned side. Tetrahydrobiopterin levels obtained on both sides remained unaffected after treatment. The D1 agonist SKF 38393 (10 μM) increased cAMP accumulation significantly in striatal slices from the lesioned and intact hemispheres in both vehicle and treatment group, which were completely inhibited by the D1 antagonist SCH 23390 (10 μM). In contrast, the ability of SKF 38393 to enhance the cAMP accumulation was blocked by the D2 agonist quinpirole (10 μM) in striatal slices from the intact hemisphere, but not from the lesioned side. In substantia nigra, no significant differences in cAMP accumulation were observed. Our data suggests that chronic L-dopa/carbidopa treatment reverses the increased dopaminergic activity and D1 receptor functional supersensitivity seen after 6- hydroxydopamine lesions, and indicates a D1 receptor-mediated action of L- dopa. After 6-hydroxydopamine lesions, there appears to be an uncoupling of the inhibitory D2 receptor- from the D1 receptor-associated cAMP accumulation in the denervated striatum. Chronic L-dopa/carbidopa treatment does not reverse this uncoupling of D1 and D2 receptors.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Pharmacology and Experimental Therapeutics|
|State||Published - 1993|
ASJC Scopus subject areas
- Molecular Medicine